{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-061512","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.515170+00:00","generated_at":"2026-06-05T01:44:49.734510+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phathom reports Q4/FY2023 results; VOQUEZNA launch nets $0.7M revenue, cash runway extended to 2026","bullets":["Q4 net revenue $0.7M from VOQUEZNA launch; cumulative prescriptions over 14,000 as of Feb 23, 2024.","Expanded term loan facility up to $300M with more favorable terms; access to $160M additional; cash runway through 2026.","Express Scripts added VOQUEZNA to formularies; ~60M commercial lives covered (~38% of U.S. commercial).","FDA accepted NDA for Non-Erosive GERD; PDUFA July 19, 2024; launch expected upon approval.","Net loss Q4 $79.6M ($46M non-GAAP adjusted); G&A up due to commercial build and stock-based comp."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-061512","json":"https://secwatch.observer/filing/0001193125-24-061512.json","markdown":"https://secwatch.observer/filing/0001193125-24-061512.md","text":"https://secwatch.observer/filing/0001193125-24-061512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524061512/0001193125-24-061512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524061512/d759734d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:44:49.734510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4432b6fb8a837379551e215201bd976e160439db","claim":"Phathom Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $0.7 million.","evidence_excerpt":"Business Update • Launched VOQUEZNA ® (vonoprazan) tablets in November 2023 for the treatment of Erosive GERD (gastroesophageal reflux disease), achieving net revenues of $0.7 million for the fourth quarter • Early physician prescribing demonstrates strong demand for VOQUEZNA • Secured expanded commercial coverage for VOQUEZNA with a top U.S. pharmacy benefit","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524061512/0001193125-24-061512-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$0.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}